vimarsana.com

Latest Breaking News On - Inhibikase therapeutics daily - Page 1 : vimarsana.com

Inhibikase Therapeutics (NYSE:IKT) PT Lowered to $23 00

Inhibikase Therapeutics (NYSE:IKT – Free Report) had its price target trimmed by HC Wainwright from $27.00 to $23.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q4 2024 […]

Inhibikase Therapeutics (NYSE:IKT) Price Target Cut to $23 00 by Analysts at HC Wainwright

Inhibikase Therapeutics (NYSE:IKT – Free Report) had its target price cut by HC Wainwright from $27.00 to $23.00 in a report issued on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q4 2024 earnings at ($0.37) […]

HC Wainwright Trims Inhibikase Therapeutics (NYSE:IKT) Target Price to $23 00

Inhibikase Therapeutics (NYSE:IKT – Free Report) had its price target trimmed by HC Wainwright from $27.00 to $23.00 in a research note issued to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q4 2024 earnings […]

Inhibikase Therapeutics (NYSE:IKT) PT Lowered to $23 00

Inhibikase Therapeutics (NYSE:IKT – Get Free Report) had its target price cut by HC Wainwright from $27.00 to $23.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Inhibikase Therapeutics Trading Up 7.5 % Shares of Inhibikase Therapeutics stock opened at $1.86 on Tuesday. The firm’s […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.